fluorouracil has been researched along with Liver Steatosis in 28 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to observe the effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil (5-FU) in fatty liver models using in vivo 31P-MRS and 19F-MRS and to compare the results." | 7.70 | Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS. ( Harada, M; Koga, K; Nishitani, H; Otsuka, H, 1999) |
| "We have described fatty liver, diagnosed by computed tomography scanning (CT) in more than 30% of patients with breast cancer who received tamoxifen." | 7.70 | Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. ( Hamada, N; Inomata, T; Kariya, S; Murata, Y; Nishioka, A; Ogawa, Y; Saibara, T; Terashima, M; Yoshida, S, 2000) |
| "Treatment with salazinic acid (25 and 50 mg/kg) and 5-Fluorouracil (20 mg/kg) started 24-hours after inoculation and was performed for 7 days." | 5.91 | Histological evaluation of the liver of mice with sarcoma-180 treated with salazinic acid. ( Aguiar Júnior, FCA; Falcão, EPS; Lira, MADC; Melo, SJ; Silva, MMD; Silva, WKM, 2023) |
| "Fatty liver is a side effect of chemotherapy that limits the ability to treat colorectal cancer (CRC) patients in the most effective way." | 5.62 | Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer. ( Bathe, O; Jacobs, R; Mazurak, VC; Monirujjaman, M; Nelson, R; Pant, A, 2021) |
| "Chemotherapy-associated steatohepatitis is attracting increasing attention because it heralds an increased risk of morbidity and mortality in patients undergoing surgery because of liver metastases." | 5.46 | Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice. ( Bosserhoff, AK; Freese, K; Hellerbrand, C; Kuecuekoktay, FS; Mahli, A; Müller, M; Schiergens, TS; Sommer, J; Teufel, A; Thasler, WE, 2017) |
| "FOLFOX-4 (folinic acid/5-fluorouracil/oxaliplatin) chemotherapy is used to treat patients with colorectal liver metastases." | 3.74 | The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. ( Aithal, GP; Aloysius, MM; Beckingham, IJ; Bessell, EM; Lobo, DN; Neal, KR; Zaitoun, AM, 2007) |
| "The purpose of this study was to observe the effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil (5-FU) in fatty liver models using in vivo 31P-MRS and 19F-MRS and to compare the results." | 3.70 | Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS. ( Harada, M; Koga, K; Nishitani, H; Otsuka, H, 1999) |
| "We have described fatty liver, diagnosed by computed tomography scanning (CT) in more than 30% of patients with breast cancer who received tamoxifen." | 3.70 | Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. ( Hamada, N; Inomata, T; Kariya, S; Murata, Y; Nishioka, A; Ogawa, Y; Saibara, T; Terashima, M; Yoshida, S, 2000) |
| "A form of non-alcoholic steatohepatitis (NASH) related to chemotherapy and otherwise known as chemotherapy-associated steatohepatitis (CASH) is closely linked to irinotecan-based therapy and is associated with inferior outcomes following hepatic surgery mainly due to hepatic insufficiency and poor regeneration." | 2.45 | Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. ( Khan, AZ; Makuuchi, M; Morris-Stiff, G, 2009) |
| "Treatment with salazinic acid (25 and 50 mg/kg) and 5-Fluorouracil (20 mg/kg) started 24-hours after inoculation and was performed for 7 days." | 1.91 | Histological evaluation of the liver of mice with sarcoma-180 treated with salazinic acid. ( Aguiar Júnior, FCA; Falcão, EPS; Lira, MADC; Melo, SJ; Silva, MMD; Silva, WKM, 2023) |
| "Fatty liver is a side effect of chemotherapy that limits the ability to treat colorectal cancer (CRC) patients in the most effective way." | 1.62 | Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer. ( Bathe, O; Jacobs, R; Mazurak, VC; Monirujjaman, M; Nelson, R; Pant, A, 2021) |
| "We report a case with steatohepatitis mimicking liver metastasis as toxicity that was not seen in study patient population." | 1.56 | Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis. ( Bozkurt Duman, B; Çil, T, 2020) |
| "Chemotherapy-associated steatohepatitis is attracting increasing attention because it heralds an increased risk of morbidity and mortality in patients undergoing surgery because of liver metastases." | 1.46 | Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice. ( Bosserhoff, AK; Freese, K; Hellerbrand, C; Kuecuekoktay, FS; Mahli, A; Müller, M; Schiergens, TS; Sommer, J; Teufel, A; Thasler, WE, 2017) |
| "Ninety-six resections for colorectal cancer hepatic metastases performed from July 2001 to July 2003 (93% > or =2 segments) were reviewed." | 1.34 | Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. ( Cattral, MS; Chan, EK; Dixon, E; Gallinger, S; Grant, DR; Greig, PD; Sahajpal, A; Taylor, BR; Vollmer, CM; Wei, A, 2007) |
| "Severe steatohepatitis can be associated with preoperative administration of irinotecan or oxaliplatin, especially in the obese." | 1.33 | Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. ( Fernandez, FG; Goodwin, JW; Hawkins, WG; Linehan, DC; Ritter, J; Strasberg, SM, 2005) |
| "Fifty-one patients with postoperative colon cancer (mean 61." | 1.33 | Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. ( Hayakawa, K; Miyake, K; Morimoto, T; Mukaihara, S; Nishino, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 6 (21.43) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 4 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Monirujjaman, M | 2 |
| Pant, A | 1 |
| Nelson, R | 1 |
| Bathe, O | 1 |
| Jacobs, R | 1 |
| Mazurak, VC | 2 |
| Renani, LB | 1 |
| Isesele, P | 1 |
| Dunichand-Hoedl, AR | 1 |
| Lira, MADC | 1 |
| Silva, MMD | 1 |
| Silva, WKM | 1 |
| Falcão, EPS | 1 |
| Aguiar Júnior, FCA | 1 |
| Melo, SJ | 1 |
| Bozkurt Duman, B | 1 |
| Çil, T | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Comsulea, M | 1 |
| Kadar, Z | 1 |
| Azamfirei, L | 1 |
| Molnar, C | 1 |
| Reddy, SK | 1 |
| Reilly, C | 1 |
| Zhan, M | 1 |
| Mindikoglu, AL | 1 |
| Jiang, Y | 1 |
| Lane, BF | 1 |
| Alexander, HR | 1 |
| Culpepper, WJ | 1 |
| El-Kamary, SS | 1 |
| Hiroshima, Y | 1 |
| Shuto, K | 1 |
| Yamazaki, K | 1 |
| Kawaguchi, D | 1 |
| Yamada, M | 1 |
| Kikuchi, Y | 1 |
| Kasahara, K | 1 |
| Murakami, T | 1 |
| Hirano, A | 1 |
| Mori, M | 1 |
| Kosugi, C | 1 |
| Matsuo, K | 1 |
| Ishida, Y | 1 |
| Koda, K | 1 |
| Tanaka, K | 1 |
| Sommer, J | 1 |
| Mahli, A | 1 |
| Freese, K | 1 |
| Schiergens, TS | 1 |
| Kuecuekoktay, FS | 1 |
| Teufel, A | 1 |
| Thasler, WE | 1 |
| Müller, M | 1 |
| Bosserhoff, AK | 1 |
| Hellerbrand, C | 1 |
| Khan, AZ | 1 |
| Morris-Stiff, G | 1 |
| Makuuchi, M | 1 |
| Chun, YS | 1 |
| Laurent, A | 1 |
| Maru, D | 1 |
| Vauthey, JN | 2 |
| Mikalauskas, S | 1 |
| Mikalauskiene, L | 1 |
| Bruns, H | 1 |
| Nickkholgh, A | 1 |
| Hoffmann, K | 1 |
| Longerich, T | 1 |
| Strupas, K | 1 |
| Büchler, MW | 1 |
| Schemmer, P | 1 |
| Pilgrim, CH | 1 |
| Brettingham-Moore, K | 1 |
| Pham, A | 1 |
| Murray, W | 1 |
| Link, E | 1 |
| Smith, M | 1 |
| Usatoff, V | 1 |
| Evans, PM | 1 |
| Banting, S | 1 |
| Thomson, BN | 1 |
| Michael, M | 1 |
| Phillips, WA | 1 |
| Jiménez, R | 1 |
| Hijona, E | 1 |
| Emparanza, J | 1 |
| Alústiza, JM | 1 |
| Hijona, L | 1 |
| Macarulla, MT | 1 |
| Portillo, MP | 1 |
| Herreros-Villanueva, M | 1 |
| Beguiristain, A | 1 |
| Arenas, J | 1 |
| Bujanda, L | 1 |
| Srivastava, J | 1 |
| Siddiq, A | 1 |
| Emdad, L | 1 |
| Santhekadur, PK | 1 |
| Chen, D | 1 |
| Gredler, R | 1 |
| Shen, XN | 1 |
| Robertson, CL | 1 |
| Dumur, CI | 1 |
| Hylemon, PB | 1 |
| Mukhopadhyay, ND | 1 |
| Bhere, D | 1 |
| Shah, K | 1 |
| Ahmad, R | 1 |
| Giashuddin, S | 1 |
| Stafflinger, J | 1 |
| Subler, MA | 1 |
| Windle, JJ | 1 |
| Fisher, PB | 1 |
| Sarkar, D | 1 |
| Fernandez, FG | 1 |
| Ritter, J | 1 |
| Goodwin, JW | 1 |
| Linehan, DC | 1 |
| Hawkins, WG | 1 |
| Strasberg, SM | 1 |
| Miyake, K | 1 |
| Hayakawa, K | 1 |
| Nishino, M | 1 |
| Morimoto, T | 1 |
| Mukaihara, S | 1 |
| Sahajpal, A | 1 |
| Vollmer, CM | 1 |
| Dixon, E | 1 |
| Chan, EK | 1 |
| Wei, A | 1 |
| Cattral, MS | 1 |
| Taylor, BR | 1 |
| Grant, DR | 1 |
| Greig, PD | 1 |
| Gallinger, S | 1 |
| Donadon, M | 1 |
| Loyer, EM | 1 |
| Charnsangavej, C | 1 |
| Abdalla, EK | 1 |
| Aloysius, MM | 1 |
| Zaitoun, AM | 1 |
| Beckingham, IJ | 1 |
| Neal, KR | 1 |
| Aithal, GP | 1 |
| Bessell, EM | 1 |
| Lobo, DN | 1 |
| Kandutsch, S | 1 |
| Klinger, M | 1 |
| Hacker, S | 1 |
| Wrba, F | 1 |
| Gruenberger, B | 1 |
| Gruenberger, T | 1 |
| Norum, J | 1 |
| Sørensen, P | 2 |
| Edal, AL | 2 |
| Madsen, EL | 2 |
| Fenger, C | 2 |
| Poulsen, MR | 2 |
| Petersen, OF | 2 |
| Kwan, W | 1 |
| Bjarnason, GA | 1 |
| Hamilton, P | 1 |
| Peppercorn, PD | 1 |
| Reznek, RH | 1 |
| Wilson, P | 1 |
| Slevin, ML | 1 |
| Gupta, RK | 1 |
| Otsuka, H | 1 |
| Harada, M | 1 |
| Koga, K | 1 |
| Nishitani, H | 1 |
| Hamada, N | 1 |
| Ogawa, Y | 1 |
| Saibara, T | 1 |
| Murata, Y | 1 |
| Kariya, S | 1 |
| Nishioka, A | 1 |
| Terashima, M | 1 |
| Inomata, T | 1 |
| Yoshida, S | 1 |
| Markoff, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
3 reviews available for fluorouracil and Liver Steatosis
| Article | Year |
|---|---|
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2009 |
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fatty Liver; Fluorouracil; Humans; Liver; Liver Neoplas | 2009 |
[Long-term therapy of liver diseases].
Topics: Aged; Anabolic Agents; Chronic Disease; Cortisone; Diet Therapy; Fatty Liver; Female; Fluorouracil; | 1972 |
3 trials available for fluorouracil and Liver Steatosis
| Article | Year |
|---|---|
Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil.
Topics: Adenocarcinoma; Colonic Neoplasms; Fatty Liver; Female; Fluorouracil; Humans; Interferon alpha-2; In | 1995 |
[Reversible liver steatosis in patients treated with 5-fluorouracil and interferon-alpha].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fatty Liver; Female; Fluo | 1997 |
22 other studies available for fluorouracil and Liver Steatosis
| Article | Year |
|---|---|
Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2021 |
Increased Expression of Hepatic Stearoyl-CoA Desaturase (SCD)-1 and Depletion of Eicosapentaenoic Acid (EPA) Content following Cytotoxic Cancer Therapy Are Reversed by Dietary Fish Oil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docosahexaenoic Acids; Eicosapentaenoic Aci | 2023 |
Histological evaluation of the liver of mice with sarcoma-180 treated with salazinic acid.
Topics: Animals; Fatty Liver; Fluorouracil; Liver; Mice; Sarcoma | 2023 |
Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fatty Liver; Female; Fluorouracil; Humans; Irinoteca | 2020 |
Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.
Topics: Acute Disease; Adenocarcinoma; Adult; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.
Topics: Antineoplastic Agents; Camptothecin; Cohort Studies; Fatty Liver; Female; Fluorouracil; Humans; Irin | 2014 |
Fractal Dimension of Tc-99m DTPA GSA Estimates Pathologic Liver Injury due to Chemotherapy in Liver Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemic | 2016 |
Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice.
Topics: Acyl-CoA Oxidase; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cells, Cultured; Dise | 2017 |
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neo | 2011 |
mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dihydrouracil D | 2011 |
Effect of neoadjuvant chemotherapy in hepatic steatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fatty Liver; Female; Fluorouracil; Huma | 2012 |
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Transformat | 2012 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square | 2005 |
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies | 2007 |
Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2007 |
5-Fluorouracil/levamisole induced intrahepatic fat infiltration imitating liver metastasis.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Diagnosis, Differential; Fatty Liver; Fluorour | 1995 |
Adjuvant therapy with fluorouracil and levamisole and liver ultrasound mimicking liver metastases.
Topics: Adult; Colonic Neoplasms; Diagnosis, Differential; Fatty Liver; Female; Fluorouracil; Humans; Levami | 1994 |
Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fatty Liver; Female; Fluorouraci | 1998 |
Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS.
Topics: Animals; Antimetabolites; Choline Deficiency; Fatty Liver; Fluorouracil; Fructose; Liver; Magnetic R | 1999 |
Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Topics: Alanine Transaminase; Alcohol Drinking; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 2000 |